LEK-8829
| LEK-8829 | |
|---|---|
| [[File:|frameless|220px|alt=|]] | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
LEK-8829 is a novel pharmaceutical compound currently under investigation for its potential therapeutic effects in the treatment of neurodegenerative disorders. It is being developed by the pharmaceutical company LEK, a subsidiary of Sandoz, which is part of the Novartis group.
Mechanism of Action[edit]
LEK-8829 is believed to function as a selective modulator of the dopaminergic system, specifically targeting the D2 and D3 dopamine receptors. By modulating these receptors, LEK-8829 may help to restore dopaminergic balance in the brain, which is often disrupted in conditions such as Parkinson's disease and schizophrenia.
Pharmacokinetics[edit]
The pharmacokinetic profile of LEK-8829 is characterized by its high oral bioavailability and moderate protein binding. It is primarily metabolized in the liver via the cytochrome P450 enzyme system, with a half-life of approximately 12 hours. The drug is excreted mainly through the renal pathway.
Clinical Trials[edit]
LEK-8829 is currently in Phase II clinical trials. Preliminary results have shown promise in improving motor function and cognitive symptoms in patients with early-stage Parkinson's disease. Further studies are needed to confirm these findings and to evaluate the long-term safety and efficacy of the drug.
Potential Side Effects[edit]
As with many dopaminergic agents, potential side effects of LEK-8829 may include nausea, dizziness, and insomnia. Rare but serious side effects could include neuroleptic malignant syndrome and tardive dyskinesia.
Research and Development[edit]
The development of LEK-8829 is part of a broader effort to create more effective treatments for neurodegenerative diseases. Researchers are particularly interested in its potential to provide symptomatic relief while also slowing disease progression.
Also see[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
- Budget GLP-1 shots
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
